Tag: TRPH-222
Stable, Site-Specific ADC Conjugation with SMARTag® Technology and Innovative Linker
Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.
TRPH-222 Shows High Response and a Favorable Safety Profile in Non-Hodgkin’s...
Updated results from its Phase 1 multi-center, open-label, monotherapy study of TRPH-222 (formerly called CAT-02-106) in heavily pre-treated patients with relapsed and/or refractory (R/R)...
ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in...
TRPH-222 (CD22-4AP), an antibody-drug conjugate (ADC) being developed by Triphase, demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients...
Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates
The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, ado-trastuzumab...
Interim Results of Phase I Clinical Trial of TRPH-222 in R/R...
The investigational drug TRPH-222 (previously known as CAT-02-106), a next-generation antibody-drug conjugate (ADC), is demonstrating early signs of efficacy in the interim results of...
Triphase’s TRPH-222 enters Clinical Phase I trials
Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in the first patient in a...
TRPH-222, a Novel Anti-CD22 ADC, has Significant Anti-Tumor Activity in NHL
A preclinical abstract describing TRPH-222, also known as CAT-02-106, an anti-CD22 antibody-drug conjugate or ADC being developed by Triphase Accelerator for the treatment of...
